Table 2.
Baseline clinical and demographic characteristics of the study cohort, as well as compliance and radiographic response (RECIST) to chemotherapy
| Characteristic | Median (range) | Number (%) |
|---|---|---|
| Age | 61 (31–75) | |
| Gender | Female | 17 (85 %) |
| Male | 3 (15 %) | |
| Race | Caucasian | 8 (40 %) |
| Hispanic | 9 (45 %) | |
| Black | 2 (10 %) | |
| Asian | 1 (5 %) | |
| ECOG Performance Status | 0 | 12 (60 %) |
| 1 | 8 (40 %) | |
| Total Fasting Cycles Completed | 1 | 3 (15 %) |
| 2 | 15 (75 %) | |
| >2 | 2 (10 %) | |
| Best objective (RECIST) response | CR | 2 (10 %) |
| PR | 6 (30 %) | |
| SD | 3 (15 %) | |
| PD | 1 (5 %) | |
| N/A0 (adjuvant therapy) | 8 (40 %) |
CR Complete response, PR Partial response, SD, Stable disease, PD Progressive disease